The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine

Oliceridine is a G protein–biased ligand at the μ‐opioid receptor in development for treatment of moderate to severe acute pain. A phase 1, open‐label, single‐dose study investigated the pharmacokinetics and safety of oliceridine 0.5 mg intravenous (IV) in subjects with end‐stage renal disease (ESRD...

Descripción completa

Detalles Bibliográficos
Autores principales: Nafziger, Anne N., Arscott, Kelly A., Cochrane, Kristina, Skobieranda, Franck, Burt, David A., Fossler, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383509/
https://www.ncbi.nlm.nih.gov/pubmed/31697049
http://dx.doi.org/10.1002/cpdd.750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383509/
https://www.ncbi.nlm.nih.gov/pubmed/31697049
http://dx.doi.org/10.1002/cpdd.750

Ejemplares similares